Triangle Securities Wealth Management’s Teva Pharmaceuticals TEVA Stock Holding History

Triangle Securities Wealth Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-4,124	Closed	-$221K	–	130
2016 Q1	$221K	Hold	4,124	–	–	0.14%	127
2015 Q4	$271K	Sell	4,124 -65	-2%	-$4.02K	0.18%	107
2015 Q3	$237K	Sell	4,189 -660	-14%	-$42.8K	0.18%	119
2015 Q2	$287K	Sell	4,849 -340	-7%	-$21K	0.2%	113
2015 Q1	$323K	Sell	5,189 -656	-11%	-$38.1K	0.22%	106
2014 Q4	$336K	Sell	5,845 -680	-10%	-$37.9K	0.24%	97
2014 Q3	$351K	Sell	6,525 -750	-10%	-$39.7K	0.27%	91
2014 Q2	$381K	Sell	7,275 -443	-6%	-$22.6K	0.29%	89
2014 Q1	$306K	Buy	7,718 +383	+5%	+$17.7K	0.28%	94
2013 Q4	$294K	Sell	7,335 -483	-6%	-$19K	0.24%	100
2013 Q3	$295K	Sell	7,818 -100	-1%	-$3.9K	0.26%	100
2013 Q2	$310K	Buy	+7,918	New	+$308K	0.23%	96

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Triangle Securities Wealth Management's TEVA Position: Q2 2016 in Review

Triangle Securities Wealth Management sold out of Teva Pharmaceuticals (TEVA) in Q2 2016, closing a stake of 4,124 shares — an estimated $221K sold.

Triangle Securities Wealth Management first reported a position in TEVA in Q2 2013 and held it in 12 quarters. The position peaked at $381K in Q2 2014. 812 funds tracked by Wall St. Rank hold TEVA as of Q2 2016.

Triangle Securities Wealth Management reported no remaining Teva Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
Triangle Securities Wealth Management sold 4,124 Teva Pharmaceuticals shares in Q2 2016, an estimated $221K.
Triangle Securities Wealth Management first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 12 quarters.
Triangle Securities Wealth Management's Teva Pharmaceuticals position peaked at $381K in Q2 2014.
812 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2016.

Based on Triangle Securities Wealth Management's 13F filing for Q2 2016, filed 7 Jul 2016.